ERBB2 and congestive heart failure: However, the treatment effect of adjuvant trastuzumab among EBC women with HER2-positive in improving the patient’s disease-free survival (DFS) and OS was controversial, as significant adverse cardiac effects (i.e., congestive heart failure, CHF and left ventricular ejection fraction, LVEF decline) were reported [11–13].